Last week during lunch, a senior colleague was rummaging through a salad and suddenly said, "The scary warning label on hormone medication is gone now, right?" My fork stopped in mid-air.

I had only skimmed the news headlines and hadn't really looked into it. So that night, I searched for the FDA announcement and related articles one by one.

To cut to the chase, the warning label hasn't completely disappeared. Some parts have been removed, while others remain unchanged.

First, let's go over the background. Since 2003, menopausal hormone therapies have carried a boxed warning, commonly referred to as a black box warning, which is the strongest level of warning.

This warning was based on the results of a large study called the Women's Health Initiative, abbreviated as WHI. Risks such as cardiovascular disease, breast cancer, and the possibility of dementia were noted within a bold border.

For over 20 years, many women have hesitated to seek treatment due to this warning, even while suffering from hot flashes and insomnia. There were also quite a few doctors reluctant to prescribe it.

Then on November 10, 2025, the FDA announced it would revise this boxed warning. They requested manufacturers to update their labels.

The FDA explained that the previous warning was applied uniformly to all products, regardless of dosage, formulation, or method of administration. Even topical products applied to the vagina carried the same warning.

On February 12, 2026, the first six products received approval for label changes. Products like Prometrium, Divigel, and Estring were included.

According to the FDA, 29 pharmaceutical companies submitted label change proposals, and additional approvals are expected to follow. This means that whether the label on the medication you are currently taking has changed may vary by product.

So, what exactly has been removed? The phrases regarding cardiovascular disease, breast cancer, and the possibility of dementia within the boxed warning have been eliminated.

The phrase "use the lowest dose for the shortest duration" has also been removed from the boxed warning. Many experts view this as a significant change.

On the flip side, some warnings remain. The boxed warning for endometrial cancer still applies to estrogen-only products that act systemically.

And it's important to clarify that just because something has been removed from the box doesn't mean that the risk information has disappeared entirely. Information regarding cardiovascular and breast cancer risks for systemic products remains in the general warning section of the label.

The new label also includes guidance regarding age and timing. It states that for those experiencing moderate to severe hot flashes, treatment may be considered if they are under 60 years old or within 10 years of starting menopause.

The FDA cited randomized study results showing reduced overall mortality and fractures among women who started treatment during this period. The key point is that "when to start" is crucial.

However, not everyone is applauding this change. The consumer group Public Citizen is open to revisions that reflect the latest evidence but criticized that many of the changes lack sufficient evidence.

I believe it's essential to consider these opposing voices as well. While the warnings may have been excessive, I'm also concerned about swinging too quickly in the opposite direction.

Honestly, I feel torn. On one hand, it's frustrating that women's health issues have been tied to one interpretation of research for so long.

Menopausal symptoms genuinely disrupt daily life. The years of waking up drenched in sweat and feeling my face flush during meetings, all brushed off as "just how it is," have been far too long.

On the other hand, I also think that just because the warning has changed doesn't mean my health status has changed. There are still valid reasons for caution for those with family histories or a history of blood clots.

So, for those who want to reconsider after seeing this news, here's what I would do. First, I would keep a record of the symptoms I'm experiencing for a few weeks.

Noting when I feel hot, how many times I wake up at night, and how my mood changes will make my consultation much more productive. In short appointments, relying solely on memory often leads to forgetting something.

Next, I would organize when menopause started and whether anyone in my family has had breast cancer or heart disease. What the new label emphasizes is ultimately timing and personal risk.

Check whether the product you are using is systemic or a topical one applied to the vagina. The warning content has changed depending on the product.

Above all, I hope that starting or stopping hormone therapy is a decision made in consultation with a doctor or pharmacist. It's not something to decide based on one internet article.

Among Korean Americans, there are many who delay going to the hospital because they feel burdened by explaining their symptoms in English. Requesting interpretation services is a patient's rightful entitlement, so don't hesitate to ask.

My stance is clear. Just because the warning has been reduced doesn't mean it's a must to start treatment, nor does it mean it's a must to avoid it due to previous warnings.

If this change opens the door to conversations about "let's not hesitate to ask," then I see that as meaningful news in itself.